Scalability: the key to making advanced therapies accessible worldwide
Discover how VIVEbiotech’s scalable platform drives innovation and brings advanced therapies closer to patients.
At VIVEbiotech, scalability is more than a concept — it’s a commitment to making advanced therapies accessible worldwide. Our modular and flexible platform currently operates at 200 m², supporting programs from early research to advanced clinical phases.
We are already designing the next-generation process for 600 m², ensuring greater capacity, smooth GMP transitions, and cost-efficient production tailored to each project’s needs.
In a recent video, Janire Arizeta, Head of Production at VIVEbiotech, explains how our expertise in lentiviral vectors allows us to anticipate challenges and deliver robust end-to-end solutions.
👉 As Janire says: ‘Scalability is our strength, built for efficiency, to make advanced therapies accessible worldwide.’ Watch the full video to learn more on YouTube or LinkedIn.